OR WAIT null SECS
Clinical program focused on reversing type 1 diabetes symptoms in patients diagnosed within six months of trial initiation
Chula Vista, Calif.-based early phase CRO will undertake DiaVacs, a biotech company testing a Type I diabetes therapy in Phase Ib/IIa trials. The double-blind, placebo-controlled study will begin by first enrolling 10 subjects who are at least 18 years of age with newly diagnosed Type I diabetes (< 6 months from diagnosis). The 15-month study commitment will have the study participants visiting the Profil facility to test DiaVacs proprietary cell-based therapy. Profil specializes in diabetes and obesity trials.
Read the full release here.